Clinical Trial Update: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 trial comparing fingolimod 0.5 mg once daily to placebo in chronic inflammatory demyelinating polyradiculoneur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2017-09-19